Migraine

>

Latest News

FDA Approves Zavegepant Intranasal CGRP Antagonist to Treat Acute Migraine in Adults
FDA Approves First Intranasal CGRP Receptor Antagonist for Adult Migraine

March 10th 2023

Zavegepant, the first FDA-approved intranasal CGRP receptor antagonist, could be available in pharmacies by July 2023.

Nerivio Prescription Wearable Cleared by FDA for Preventive Treatment of Migraine
Nerivio Prescription Wearable Cleared by FDA for Preventive Treatment of Migraine

March 2nd 2023

Zavegepant Intranasal Migraine Agent Meets Coprimary Endpoints in Phase 3 Trial, Pfizer Announces
Zavegepant Intranasal Migraine Agent Meets Coprimary Endpoints in Phase 3 Trial, Pfizer Announces

February 17th 2023

Oral Superabsorbent Hydrogel Cuts Risk for Type 2 Diabetes
Daily Dose: Migraine and Pregnancy Complications

February 6th 2023

Eptinezumab Significantly Reduced Patient-reported Migraine Impact on HRQoL in Medication Overuse Headache and Chronic Migraine
Eptinezumab Significantly Reduced Patient-reported Migraine Impact on HRQoL in Medication Overuse Headache and Chronic Migraine

February 6th 2023

Video Interviews
Podcasts

More News

© 2023 MJH Life Sciences

All rights reserved.